πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

163 results for β€œArk” Clear

  1. 5-(1-(2-[18F] fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen

    Disc Medicine

    Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson

    phase 2 small molecule active

    1 trial

  2. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  3. AMBROXOL , Microcrystalline cellulose

    Disc Medicine

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  4. ARD-101

    Ark Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  5. ARD-101

    Ark Therapeutics

    Bariatric Surgery

    phase 2 small molecule completed

    1 trial

  6. ARD-101

    Ark Therapeutics

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  7. ARICEPT 10mg comprimidos recubiertos con pelΓ­cula

    Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  8. ARK-E021 5%

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  9. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  10. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  11. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  12. Avastin 25 mg/ml concentrate for solution for infusion., ACIDO VALPROICO E SODIO VALPROATO ratiopharm 500 mg compresse a rilascio prolungato, Oxaliplatino Accord 5 mg/ml concentrato per soluzione per infusione, FLUOROURACILE PFIZER 50 mg/mL, solution Γ  diluer pour perfusion, Capecitabina Glenmark 150 mg comprimidos recubiertos con pelΓ­cula EFG

    Fondazione Telethon ETS

    Patients with ras-mutated metastatIc colorectal cancer

    phase 2 small molecule active

    1 trial

  13. B-CIT and SPECT imaging

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  14. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  15. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

  16. Buprenorphine hydrochloride marketed sublingual tablet (Subutex)

    Indivior Europe Limited

    Opioid Dependency

    phase 2 small molecule completed

    1 trial

  17. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  18. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  19. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  20. DAAOI-P

    China SXT Pharmaceuticals

    Parkinson's Disease With Dementia

    phase 2 small molecule completed

    1 trial

  21. Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

    Pharma Mar S.A.

    Parkinson's disease

    phase 2 other active

    1 trial

  22. Exercise Programme

    United Therapeutics Europe Ltd

    Parkinson's Disease

    phase 2 other completed

    1 trial

  23. FRΞ± peptide plus Adjuvant (GM-CSF)

    Marker Therapeutics

    Platinum Sensitive Ovarian Cancer

    phase 2 mab terminated

    1 trial

  24. Green Tea Polyphenols (EGCG/ECG)

    China SXT Pharmaceuticals

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources